Dalcetrapib vs Obicetrapib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: CETP · full Atherosclerotic Cardiovascular Disease pipeline
Dalcetrapib
Developed by DalCor Pharmaceuticals under a licence from Roche
NCT01516541 · Phase 3 · completed
The study was randomized and double-blind, compared dalcetrapib with placebo, and enrolled 2,220 participants. Its primary endpoint was a hard clinical composite cardiovascular outcome, but the comparison cannot be judged because trial results have not been posted.
Next expected readout: August 2027 · NCT05918861 (registry estimate)
Reported efficacy
Incidence of Cardiovascular Mortality and Morbidity (From date of randomization to first event up to 48 months): Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). (missed)
Result source: NCT00658515
Obicetrapib
Marketed by A. Menarini under a licence from NewAmsterdam Pharma
NCT05142722 · Phase 3 · completed
Participants were randomized 2:1 to obicetrapib or placebo and the trial was quadruple-blinded, with 2,530 participants enrolled. The primary LDL-cholesterol endpoint was met, with a statistically significant treatment difference, but LDL cholesterol is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure, supporting a moderate grade.
Next expected readout: November 2026 · NCT06496243 (registry estimate)
Reported efficacy
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571) (met)
Result source: NCT05142722
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dalcetrapib | Obicetrapib |
|---|---|---|
| LDL-C, % change | —Not posted · NCT01516541 | -29.9% vs 2.7%−32.6 vs placeboNCT0514272268 other results
|
| Non-HDL-C, % change | —Not posted · NCT01516541 | -22.4% vs 0.6%−23 vs placeboNCT0514272223 other results
|
| ApoB, % change | —Not posted · NCT01516541 | -15.6% vs -1.8%−13.8 vs placeboNCT0514272238 other results
|
| Lp(a), % change | —Not posted · NCT01516541 | -0.5% vs 13.7%−14.1 vs placeboNCT051427223 other results
|
| 3-point MACE (% with event) | —Not posted · NCT01516541 | —Trial running · NCT05202509 |
LDL-C, % change
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib
- -29.9% vs 2.7%−32.6 vs placeboNCT05142722
68 other results
- -36.0% vs 0.3% NCT05425745
- -45.6% vs 3.0% NCT06005597
- -28.8% vs 3.0% NCT06005597
- -45.6% vs -17.6% NCT06005597
- -25.3% vs -1.3% NCT05142722
- -29.1% vs 4.7% NCT05142722
- -31.1% vs 10.3% NCT05425745
- -31.8% vs 6.0% NCT05425745
- -36.8% vs -0.8% NCT05421078
- -45.8% vs -0.9% NCT05421078
- -36.6% vs -0.5% NCT05421078
- -36.3% vs 0.4% NCT05421078
- -43.7% vs 0.7% NCT05421078
- -36.1% vs 0.7% NCT05421078
- -43.4% vs -5.5% NCT04753606
- -45.6% vs 0% NCT04753606
- -44.2% vs -5% NCT04753606
- -46.1% vs -7.1% NCT04753606
- -50.8% vs -6.5% NCT04753606
- -46.8% vs -6.7% NCT04753606
- -33.8% vs -0.8% NCT05421078
- -31.9% vs -0.9% NCT05421078
- -33.8% vs -0.5% NCT05421078
- -30.5% vs 0.4% NCT05421078
- -30.4% vs 0.7% NCT05421078
- -30.5% vs 0.7% NCT05421078
- -38.0% vs -5.5% NCT04753606
- -42.9% vs 0% NCT04753606
- -38.0% vs -5% NCT04753606
- -36.0% vs -7.1% NCT04753606
- -41.5% vs -6.5% NCT04753606
- -35.6% vs -6.7% NCT04753606
- -25.9% vs -0.8% NCT05421078
- -24.8% vs -0.9% NCT05421078
- -26.3% vs -0.5% NCT05421078
- -26.1% vs 0.4% NCT05421078
- -26.0% vs 0.7% NCT05421078
- -26.5% vs 0.7% NCT05421078
- -59.1% vs -0.8% NCT05266586
- -63.4% vs -6.3% NCT05266586
- -59.2% vs -0.8% NCT05266586
- -59.5% vs -1.5% NCT05266586
- -62.8% vs -4.0% NCT05266586
- -59.7% vs -1.5% NCT05266586
- -45.6% vs -0.2% NCT04770389
- -52.0% vs -1.4% NCT04770389
- -43.5% vs 1.4% NCT04770389
- -44.4% vs -1.5% NCT04770389
- -51.4% vs -2% NCT04770389
- -44.1% vs -0.8% NCT04770389
- -39.4% vs -0.8% NCT05266586
- -43.5% vs -6.3% NCT05266586
- -39.2% vs -0.8% NCT05266586
- -39.0% vs -1.5% NCT05266586
- -43.5% vs -4.0% NCT05266586
- -38.8% vs -1.5% NCT05266586
- -31.9% vs -0.2% NCT04770389
- -34.4% vs -1.4% NCT04770389
- -32.0% vs 1.4% NCT04770389
- -27.9% vs -1.5% NCT04770389
- -30.1% vs -2% NCT04770389
- -29.0% vs -0.8% NCT04770389
- -45.6% vs -12.7% NCT04770389
- -52.0% vs -14.8% NCT04770389
- -43.5% vs -13.4% NCT04770389
- -31.9% vs -12.7% NCT04770389
- -34.4% vs -14.8% NCT04770389
- -32.0% vs -13.4% NCT04770389
Non-HDL-C, % change
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib
- -22.4% vs 0.6%−23 vs placeboNCT05142722
23 other results
- -24.6% vs 3.7% NCT05142722
- -26.6% vs 2.8% NCT05142722
- -25.8% vs 11.6% NCT05425745
- -27.1% vs 5.9% NCT05425745
- -31.6% vs 2.8% NCT05425745
- -42.4% vs 2.7% NCT06005597
- -27.2% vs 2.7% NCT06005597
- -42.4% vs -17.0% NCT06005597
- -30.3% vs -1.8% NCT05421078
- -37.0% vs -0.4% NCT05421078
- -30.3% vs -1.7% NCT05421078
- -39.3% vs -4.2% NCT04753606
- -44.4% vs -3.5% NCT04753606
- -39.9% vs -3.8% NCT04753606
- -30.4% vs -1.8% NCT05421078
- -29.8% vs -0.4% NCT05421078
- -30.1% vs -1.7% NCT05421078
- -34.3% vs -4.2% NCT04753606
- -38.9% vs -3.5% NCT04753606
- -34.4% vs -3.8% NCT04753606
- -25.4% vs -1.8% NCT05421078
- -23.7% vs -0.4% NCT05421078
- -25.7% vs -1.7% NCT05421078
ApoB, % change
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib
- -15.6% vs -1.8%−13.8 vs placeboNCT05142722
38 other results
- -16.1% vs 2.2% NCT05142722
- -17.8% vs 1.1% NCT05142722
- -17.6% vs 8.2% NCT05425745
- -18.3% vs 6.0% NCT05425745
- -21.4% vs 2.9% NCT05425745
- -26.9% vs 2.3% NCT06005597
- -17.5% vs 2.3% NCT06005597
- -26.9% vs -12.7% NCT06005597
- -21.7% vs 0.5% NCT05266586
- -24.2% vs -2.0% NCT05266586
- -21.6% vs 0.7% NCT05266586
- -26.7% vs -1.2% NCT05421078
- -29.7% vs -0.4% NCT05421078
- -26.3% vs -1.4% NCT05421078
- -27.2% vs -4.7% NCT04753606
- -29.8% vs -2.6% NCT04753606
- -28.1% vs -4.1% NCT04753606
- -24.5% vs -1.2% NCT05421078
- -21.4% vs -0.4% NCT05421078
- -23.9% vs -1.4% NCT05421078
- -22.6% vs -4.7% NCT04753606
- -24.4% vs -2.6% NCT04753606
- -22.4% vs -4.1% NCT04753606
- -19.8% vs -1.2% NCT05421078
- -22.5% vs -0.4% NCT05421078
- -20.4% vs -1.4% NCT05421078
- -34.7% vs 0.5% NCT05266586
- -34.4% vs -2.0% NCT05266586
- -35.0% vs 0.7% NCT05266586
- -31.6% vs -1.2% NCT04770389
- -34.8% vs -0.9% NCT04770389
- -29.7% vs -0.1% NCT04770389
- -22.1% vs -1.2% NCT04770389
- -23.5% vs -0.9% NCT04770389
- -22.5% vs -0.1% NCT04770389
- -31.6% vs -8.8% NCT04770389
- -34.8% vs -8.9% NCT04770389
- -29.7% vs -8.9% NCT04770389
Lp(a), % change
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib
- -0.5% vs 13.7%−14.1 vs placeboNCT05142722
3 other results
- -32.3% vs -0.9% NCT05142722
- -29.9% vs 24.4% NCT05425745
- -35.4% vs 10.5% NCT05425745
3-point MACE (% with event)
- Dalcetrapib
- —Not posted · NCT01516541
- Obicetrapib
- —Trial running · NCT05202509
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Dalcetrapib: 4 of 5 rows · Obicetrapib: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dalcetrapib | Obicetrapib |
|---|---|---|
| HDL-C percent change · % of baseline | 13.92% (n=72) vs 0.73% (n=73) placebo @ 12wk900mga,b,c,d NCT00697203 · Phase 2 · registry result, not featured evidence show 2 more doses11.9% (n=67) vs 0.73% (n=73) placebo @ 12wk600mg NCT00697203 · Phase 2 · registry result, not featured evidence 6.58% (n=75) vs 0.73% (n=73) placebo @ 12wk300mg NCT00697203 · Phase 2 · registry result, not featured evidence | 136.87% (n=1685) vs 0.61% (n=843) placebo @ 12wk10mgb,c,d NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 1 other source trial139.92% (n=234) vs 1.26% (n=118) placebo @ 12wk10 mg NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 |
| Dropout rate | 2.1%e NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 4 more results17.2% NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2 10.8%900mg NCT00697203 · Phase 2 · registry result, not featured evidence 8.8%600mg NCT00697203 · Phase 2 · registry result, not featured evidence 11.8%300mg NCT00697203 · Phase 2 · registry result, not featured evidence | 5.1%10mgf NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 12 more results4.2%10 mg NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2%Fixed Dose Combination NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 2.9%Monotherapy Obicetrapib NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%10 mg NCT05421078 · Phase 2 · registry result, not featured evidence 0%5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 0%2.5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 7.7%10 mg NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy 5%Combination Therapy NCT05266586 · Phase 2 · registry result, not featured evidence · combination 0%10 mg NCT04753606 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04753606 · Phase 2 · registry result, not featured evidence 18.5%Combination Therapy NCT04770389 · Phase 2 · registry result, not featured evidence · combination 7.1%Obicetrapib Monotherapy NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | —e NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 4 more results— NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2 —900mg NCT00697203 · Phase 2 · registry result, not featured evidence —600mg NCT00697203 · Phase 2 · registry result, not featured evidence —300mg NCT00697203 · Phase 2 · registry result, not featured evidence | 0.1%10mgf NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 12 more results0.4%10 mg NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —Fixed Dose Combination NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —Monotherapy Obicetrapib NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —10 mg NCT05421078 · Phase 2 · registry result, not featured evidence —5 mg NCT05421078 · Phase 2 · registry result, not featured evidence —2.5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 5.1%10 mg NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy 2.5%Combination Therapy NCT05266586 · Phase 2 · registry result, not featured evidence · combination 0%10 mg NCT04753606 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04753606 · Phase 2 · registry result, not featured evidence 7.4%Combination Therapy NCT04770389 · Phase 2 · registry result, not featured evidence · combination 0%Obicetrapib Monotherapy NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy |
| Serious AEs | 12.9%e NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 4 more results31.3% NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2 4.1%900mg NCT00697203 · Phase 2 · registry result, not featured evidence 2.9%600mg NCT00697203 · Phase 2 · registry result, not featured evidence 2.6%300mg NCT00697203 · Phase 2 · registry result, not featured evidence | 12.5%10mgf NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 12 more results5.6%10 mg NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.9%Fixed Dose Combination NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 5.9%Monotherapy Obicetrapib NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%10 mg NCT05421078 · Phase 2 · registry result, not featured evidence 4%5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 0%2.5 mg NCT05421078 · Phase 2 · registry result, not featured evidence 2.6%10 mg NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy 0%Combination Therapy NCT05266586 · Phase 2 · registry result, not featured evidence · combination 0%10 mg NCT04753606 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04753606 · Phase 2 · registry result, not featured evidence 0%Combination Therapy NCT04770389 · Phase 2 · registry result, not featured evidence · combination 0%Obicetrapib Monotherapy NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | e chest pain 10.1% (placebo 7.8%) diarrhea 8.6% (placebo 5.8%) hypertension 8% (placebo 4.1%) NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 | 10mgf hypertension 4.9% (placebo 3.9%) covid-19 4.8% (placebo 5.7%) upper respiratory tract infection 2.9% (placebo 3.9%) NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 12 more results10 mg influenza 9% (placebo 5.9%) covid-19 6.4% (placebo 6.8%) nasopharyngitis 6.4% (placebo 4.2%) NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 diarrhoea 4.9% (placebo 0%) covid-19 3.9% (placebo 1%) fatigue 3.9% (placebo 1%) NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 hypertension 8.8% (placebo 2.9%) arthralgia 6.9% (placebo 2.9%) headache 5.9% (placebo 2%) NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 10 mg back pain 7.7% (placebo 11.5%) nasopharyngitis 7.7% (placebo 11.5%) rhinitis allergic 7.7% (placebo 0%) NCT05421078 · Phase 2 · registry result, not featured evidence 5 mg blood glucose increased 4% (placebo 0%) blood pressure increased 4% (placebo 0%) chest pain 4% (placebo 0%) NCT05421078 · Phase 2 · registry result, not featured evidence 2.5 mg diabetes mellitus 8% (placebo 0%) hypoglycaemia 8% (placebo 0%) abdominal distension 4% (placebo 0%) NCT05421078 · Phase 2 · registry result, not featured evidence 10 mg abdominal pain 2.6% (placebo 0%) abdominal pain upper 2.6% (placebo 0%) acute myocardial infarction 2.6% (placebo 0%) NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy nausea 5% (placebo 5%) arthralgia 2.5% (placebo 2.5%) bronchitis 2.5% (placebo 0%) NCT05266586 · Phase 2 · registry result, not featured evidence · combination 10 mg arthralgia 2.5% (placebo 2.5%) arthropod sting 2.5% (placebo 0%) cardiomegaly 2.5% (placebo 0%) NCT04753606 · Phase 2 · registry result, not featured evidence 5 mg fatigue 5% (placebo 5%) hypertension 5% (placebo 0%) type 2 diabetes mellitus 5% (placebo 0%) NCT04753606 · Phase 2 · registry result, not featured evidence diarrhoea 7.4% (placebo 0%) abdominal pain 3.7% (placebo 0%) back pain 3.7% (placebo 0%) NCT04770389 · Phase 2 · registry result, not featured evidence · combination covid-19 3.6% (placebo 0%) flatulence 3.6% (placebo 0%) onychomycosis 3.6% (placebo 0%) NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for 3 of these studies.
- fPopulation comparability has not been reviewed for 9 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dalcetrapib
show 2 more results
Obicetrapib
show 68 more results
show 38 more results
show 23 more results
show 3 more results
show 5 more results
show 5 more results
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalcetrapib's landscape · Obicetrapib's landscape